Avacincaptad pegol sodium is used for the treatment of geographic atrophy (GA) and is under investigation for age-related macular degeneration (AMD) by inhibiting complement factor 5 (C5) cleavage, thereby limiting inflammatory stimulation, membrane attack complex (MAC) formation, and dysregulated cell apoptosis, while preserving early steps of the complement system.